Testing a Primary Care Model for the Treatment of Opioid Dependence Using Long-acting Injectable Naltrexone (Vivitrol).
NCT00675532 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL
Last updated 2013-07-22
Summary
In opioid dependent patients treated with long-acting injectable naltrexone (Vivitrol ®), we will compare the efficacy of a primary care model of counseling (Condition 1) versus individualized cognitive-behavioral psychotherapy (Condition 2) for the treatment of opioid dependence. Treatment will last 12 weeks, and participants will be given 380mg of naltrexone per injection (3 injections in total; each lasting 4 weeks). Primary outcomes will be 1) percent of opioid negative urines and 2) treatment compliance as measured by attendance and time in treatment. Secondary outcomes are opiate craving, opiate withdrawal symptoms, perceived stress scores, severity of addiction problems, and patient satisfaction. Findings will elucidate whether injectable, long-acting naltrexone would be safe and effective in a primary care setting where medication would be administered in the absence of traditional cognitive-behavioral psychotherapy and indicate whether cognitive-behavioral psychotherapy adds to treatment effects above and beyond primary care counseling. If positive, this small controlled study will provide effect size estimates for a larger trial to assess Vivitrol ® in a primary care setting.
Conditions
- Drug Dependence
Interventions
- BEHAVIORAL
-
Primary Care Counseling
Subjects in this condition will attend bi-weekly 15 minute sessions with the study nurse for primary care counseling which is a brief manual-guided, medically focused counseling approach to the treatment of opioid dependent individuals seen in primary care settings. The brief counseling sessions involve repeated support for and monitoring of medication compliance, and the provision of advice regarding established methods for coping with psychological and social factors that lead to drug use.
- BEHAVIORAL
-
Cognitive-behavioral psychotherapy
Subjects in the CBT condition will participate in bi-weekly 50-minute-long individualized cognitive-behavioral psychotherapy sessions with a CBT trained clinician. The general purpose of the therapy is to: (1) acquire information about important concepts and aspects of recovery from opioid addiction; (2) increase self-awareness of specific problems and issues in relation to addiction and recovery, and (3) learn new coping skills to deal with problems contributing to or resulting from the addiction and to improve overall psychosocial functioning. The primary focus of this approach is to provide patients with frequent supportive contact and to teach cognitive-behavioral relapse prevention skills.
Sponsors & Collaborators
-
Yale University
lead OTHER
Principal Investigators
-
David Fiellin, Ph.D. · Yale University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-05-31
- Primary Completion
- 2013-05-31
- Completion
- 2013-08-31
Countries
- United States
Study Locations
More Related Trials
-
Memantine as a Supplement to Naltrexone in Treating Heroin Dependence
NCT00476242 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
The Feasibility of the OpiVenture Program for Clients Undergoing Opioid Agonist Therapy
NCT06211972 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Counseling for Primary Care Office-based Buprenorphine
NCT00595764 ·Status: COMPLETED ·Phase: PHASE4
-
Subthreshold Opioid Use Disorder Prevention (STOP) Trial
NCT04218201 ·Status: COMPLETED ·Phase: NA
-
Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry
NCT01999946 ·Status: COMPLETED ·Phase: PHASE4
-
Therapy for People With Opioid Use Disorder
NCT06008769 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Aprepitant Effects in Intravenous Heroin Dependence
NCT01527994 ·Status: COMPLETED ·Phase: PHASE1
-
Distress Tolerance and HIV Prevention With XR-NTX Initiation in Opioid Dependence
NCT02602795 ·Status: COMPLETED ·Phase: NA
-
Computerized Anxiety Sensitivity Treatment for Opioid Use Disorders
NCT03944850 ·Status: COMPLETED ·Phase: NA
-
Effectiveness of Naltrexone and Lofexidine in Treating Detoxified Heroin Addicts - 1
NCT00218530 ·Status: COMPLETED ·Phase: PHASE1
-
Workforce and System Change to Treat Adolescent Opioid Use Disorder Within Integrated Pediatric Primary Care
NCT06477848 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
Developing a Telehealth Model to Improve Treatment Access for Rural Veterans With Substance Use Disorders
NCT05348317 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
The MOUD Plus Pilot: Counseling and Peer Support to Support Retention for Medically Complex Patients With Opioid Use Disorder Seen In Primary Care
NCT06837662 ·Status: RECRUITING ·Phase: NA
-
Scalable Digital Delivery of Evidence-based Training for Professionals to Maximize Treatment Rates of OUD in Families
NCT05875142 ·Status: COMPLETED ·Phase: NA
-
Comprehensive Opioid Management in Patient Aligned Care Teams
NCT01737073 ·Status: WITHDRAWN ·Phase: NA
-
Resilience Among Individuals With Opioid Use Disorder
NCT06954402 ·Status: RECRUITING ·Phase: NA
-
A Strategy to Improve Success of Treatment Discontinuation in Buprenorphine Responders
NCT03232346 ·Status: COMPLETED ·Phase: PHASE3
-
Naltrexone and Behavioral Drug and HIV Risk Reduction Counseling in Russia
NCT01389167 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of a Peer Recovery Support Program Adapted to Target Retention in Clinic-based Medication for Opioid Use Disorder Treatment
NCT07197801 ·Status: RECRUITING ·Phase: NA
-
Using AI and Peer Coaching to Address Racial Disparities Among People Who Use Opioids
NCT06569667 ·Status: RECRUITING ·Phase: NA
-
Anxiety Sensitivity Treatment for Heroin Users
NCT01196312 ·Status: COMPLETED ·Phase: NA
-
Medications for Opioid Use Disorders (MOUD) Via Telemedicine
NCT03566459 ·Status: COMPLETED
-
Buprenorphine Integration Research and Community Health
NCT05668780 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Intervening on Opioid Use and Loneliness
NCT06458335 ·Status: RECRUITING ·Phase: NA
-
Clinical Trial of Integrated Treatment for Pain and Opioid Dependence
NCT00634803 ·Status: COMPLETED ·Phase: PHASE1/PHASE2